Log in | Register

Causes and risk factors of death in patients with thrombotic microangiopathies

Vincent Peigne| Pierre Perez| Matthieu Resche Rigon| Eric Mariotte| Emmanuel Canet| Jean-Paul Mira| Paul Coppo| Agnès Veyradier| Elie Azoulay
Original
Volume 38, Issue 11 / November , 2012

Pages 1810 - 1817

Abstract

Purpose

Although plasma therapy of thrombotic micro-angiopathies (TMAs) has dramatically improved survival, the outcome remains fatal in up to 15 % of patients. We investigated the causes and risk factors of death in patients with TMA.

Methods

Retrospective matched case–control national-registry study of 57 patients who died within 180 days of TMA diagnosis and 48 survivors matched on age, gender, and baseline platelet count and creatinine level. The study period was 1995–2007. Factors associated with mortality were identified using a conditional logistic regression model.

Results

Median time from TMA symptom onset to death was 7 (5–14) days. The leading causes of death were nosocomial infections, myocardial infarction, stroke, and pulmonary embolism. Cases and controls did not differ significantly regarding haemolysis parameters, ADAMTS13 activity, or neurological or gastrointestinal involvement. TMA was more frequently related to HIV or cancer in patients who died. Compared to survivors, non-survivors more often had cardiac involvement at diagnosis (38 vs. 6 %, p = 0.03) and less often received plasma exchange therapy (60 vs. 92 %, p = 0.004). Only two factors were independently associated with mortality by multivariate analysis: cardiac involvement at diagnosis (odds ratio, 5.96; 95 % confidence interval, 1.06–33.4) and plasma exchange therapy (odds ratio, 0.25; 95 % confidence interval, 0.06–0.99).

Conclusion

Our data emphasise the adverse prognostic significance of cardiac abnormalities and support routine plasma exchange in patients with TMA. Given the high risk of cardiac and neurological complications, adequate monitoring should be proposed to these patients in appropriate hospital settings.

Keywords

References

  1. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600
    • View reference on PubMed
    • View reference on publisher's website
  2. Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325:398–403
    • View reference on PubMed
    • View reference on publisher's website
  3. George JN, Vesely SK, Terrell DR (2004) The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 41:60–67
    • View reference on PubMed
    • View reference on publisher's website
  4. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435
    • View reference on PubMed
    • View reference on publisher's website
  5. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594
    • View reference on PubMed
    • View reference on publisher's website
  6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584
    • View reference on PubMed
    • View reference on publisher's website
  7. Veyradier A, Meyer D (2005) Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 3:2420–2427
    • View reference on PubMed
    • View reference on publisher's website
  8. Fujimura Y, Matsumoto M (2010) Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998–2008. Intern Med 49:7–15
    • View reference on PubMed
    • View reference on publisher's website
  9. Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwège V, Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P, des Microangiopathies Thrombotiques (TMA-Rare Diseases Reference Center) (2008) Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Scand J Immunol 68:337–344
    • View reference on PubMed
    • View reference on publisher's website
  10. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393–397
    • View reference on PubMed
    • View reference on publisher's website
  11. Coppo P, Bussel A, Charrier S, Adrie C, Galicier L, Boulanger E, Veyradier A, Leblanc T, Alberti C, Azoulay E, Le Gall JR, Schlemmer B (2003) High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 82:27–38
    • View reference on publisher's website
  12. Darmon M, Azoulay E, Thiery G, Ciroldi M, Galicier L, Parquet N, Veyradier A, Le Gall JR, Oksenhendler E, Schlemmer B (2006) Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med 34:2127–2133
    • View reference on PubMed
    • View reference on publisher's website
  13. Zhan H, Streiff MB, King KE, Segal JB (2010) Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion 50:868–874
    • View reference on PubMed
    • View reference on publisher's website
  14. Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127:834–839
    • View reference on PubMed
  15. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K (2004) Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83:233–244
    • View reference on publisher's website
  16. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98:1765–1772
    • View reference on PubMed
    • View reference on publisher's website
  17. Brand J (1999) Development, implementation and evaluation of multiple imputation strategies for the statistical analysis of incomplete data sets. Leiden and Erasmus University, Rotterdam
  18. van Buuren S, Boshuizen H, Knook D (1999) Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18:681–694
    • View reference on PubMed
    • View reference on publisher's website
  19. Gami AS, Hayman SR, Grande JP, Garovic VD (2005) Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med 118:544–547
    • View reference on PubMed
    • View reference on publisher's website
  20. Hawkins BM, Abu-Fadel M, Vesely SK, George JN (2008) Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 48:382–392
    • View reference on PubMed
  21. Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, Singh P (2009) Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol 33:213–216
    • View reference on publisher's website
  22. Hughes C, McEwan JR, Longair I, Hughes S, Cohen H, Machin S, Scully M (2009) Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost 7:529–536
    • View reference on PubMed
    • View reference on publisher's website
  23. Sane DC, Streer NP, Owen J (2009) Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: pathophysiology and rationale for specific therapy. Eur J Haematol 82:83–92
    • View reference on PubMed
    • View reference on publisher's website
  24. Perez L, Ramappa P, Guzman JA (2008) Myocardial injury in thrombotic thrombocytopenic purpura: a frequent, perplexing complication. Int J Cardiol 128:257–260
    • View reference on PubMed
    • View reference on publisher's website
  25. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, Tacconi F, Ascari E (1997) Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 82:429–435
    • View reference on PubMed
  26. Thachil J (2010) The myths about platelet transfusions in immune-mediated thrombocytopenias. Br J Haematol 150:494–495
    • View reference on PubMed
  27. Gottschall JL, Pisciotta AV, Darin J, Hussey CV, Aster RH (1981) Thrombotic thrombocytopenic purpura: experience with whole blood exchange transfusion. Semin Thromb Hemost 7:25–32
    • View reference on PubMed
    • View reference on publisher's website
  28. Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT (1981) Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 246:1931–1933
    • View reference on PubMed
    • View reference on publisher's website
  29. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B, George JN (2009) Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 49:873–887
    • View reference on PubMed
    • View reference on publisher's website
  30. Benhamou Y, Assie’ C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provôt F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, Azoulay E, Rottensteiner H, Veyradier A, Coppo P (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica (Epub ahead of print)

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement